Impact of Landmark Responses on 3-Year Outcomes in CP-CML Patients in the Ponatinib PACE Trial

Ponatinib is a potent oral tyrosine kinase inhibitor (TKI) approved for patients with refractory CML/Ph+ ALL, or with T315I. In first- and second-line settings with other TKIs, landmark responses have been correlated with positive long-term outcomes; data are limited for heavily pretreated populations.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Moshe Talpaz, Martin M üller, Michele Baccarani, Michael Deininger, François Guilhot, Andreas Hochhaus, Timothy Hughes, Neil Shah, Stephanie Lustgarten, Victor Rivera, Tim Clackson, Frank Haluska, Jorge Cortes Source Type: research